Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 1 · 33.3%Moderate 0 · 0%High 0 · 0%

Eculizumab vs placebo or alternative treatment

Death · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Eculizumab vs placebo

Death · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset

Eculizumab showed no clear difference in death compared with placebo (low certainty).

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
RR 1.5 [0.08, 26.86]
2 studies · 38 participants
Low

Death or disability after 12 months In the absence of data at 12 months, we report the outcome at 6 months · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset

It is very uncertain whether eculizumab changes death or disability after 12 months In the absence of data at 12… compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
RR 1.21 [0.15, 10.11]
2 studies · 38 participants
Very low